Board of Directors
George Jenkins, Chairman
From 1987 to 2005, George was a general partner of Apax Partners, a leading global private equity firm where he served as chief operating officer overseeing a multi-billion dollar venture capital and private equity investment portfolio. Since 2006, Mr. Jenkins has been an active private investor primarily funding technology-based start-ups. Mr. Jenkins has been or currently serves as a board member of numerous public and private companies, including SkinMedica (acquired by Allergan), Colorescience, Flower Orthopedics, Power Survey, Sunglass Hut, and Spyder Active Sports. Prior to joining Apax, Mr. Jenkins was a banker managing banking facilities in Europe. Mr. Jenkins earned a B.A. in economics and accounting from Lafayette College where he currently serves as a trustee.
Elaine J. Heron, Ph.D.
Dr. Heron served as chair and chief executive officer of Amplyx Pharmaceuticals, Inc., a clinical stage drug development company from February 2009 until October 2015, and she continues to serve as member of that company’s board. She is also a member of the boards of directors of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a therapeutics company with annual sales over $1 billion and Vala Sciences, a private biotechnology tools company. From July 2001 to October 2008, Dr. Heron was chair and chief executive officer of Labcyte Inc., a private biotechnology tools company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology tools company, including the positions of general manager and vice president of sales and marketing. Dr. Heron earned a B.S. in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.
Tim Henkel, M.D., Ph.D.
Tim Henkel, M.D., Ph.D., is the chief medical officer of VenatoRx, a leading venture-backed start-up company focused on the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral, immunomodulatory and oncology drugs. He has successfully developed biologics, small molecules and natural products in the US and Europe. Prior to joining VenatoRx, Dr. Henkel was executive vice president of research and development at Ceptaris Therapeutics (acquired by Actelion). At Ceptaris, Tim architected the clinical development plan and regulatory strategy for VALCHLOR, a novel topical mechlorethamine gel for the treatment of cutaneous T-cell lymphoma. Dr. Henkel was also executive vice president of research and development at Ception Therapeutics (acquired by Cephalon), executive vice president and chief medical officer of Vicuron Pharmaceuticals (acquired by Pfizer), and vice president of worldwide anti-infective clinical development for SmithKline Beecham.
Prior to joining SmithKline Beecham, Dr. Henkel was an assistant professor of internal medicine and infectious diseases at Washington University in St. Louis, where he also earned his board certifications in both internal medicine and in infectious diseases. He received his M.D. and a Ph.D. in immunology from Washington University in St. Louis, and his B.S. in chemistry and biology from Rhodes College.
David Tierney, M.D.
David Tierney, M.D. currently serves as the chief executive officer and member of the board of BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on the dermatology market. Previously he was the president & CEO of ICON Bioscience, a venture-backed ophthalmic therapy company. Prior to ICON, Dr. Tierney served as president & COO and a member of the board of directors of Oceana Therapeutics, a specialty therapeutic company he co-founded in mid-2008. Oceana was acquired in December 2011 by Salix Pharmaceuticals for $300 million. Dr. Tierney also served as chief executive officer and a director of Valera Pharmaceuticals, until it was acquired by Indevus Pharmaceuticals. Dr. Tierney served as president of Biovail Technologies where he had responsibility for all of Biovail's research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was senior vice president of drug development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team.
Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland. David Tierney is the recipient of two Ernst & Young Entrepreneur of the Year® awards, first in 2005 and again in 2011. He was featured in the inaugural 2010 Irish Life Science 50 and in 2005, 2006, and 2011 was named one of the most inspiring people in the health sciences by PharmaVOICE 100. Dr. Tierney also serves on the board of directors of Catalyst Pharmaceuticals (NASDAQ: CPRX) and Kempharm (NASDAQ: KMPH).
Todd Davis is a founding managing director at HealthCare Royalty Partners, a global healthcare investment firm. He has thirty years of experience working in and investing in the pharmaceutical and biotechnology industries. Over the course of his career, Mr. Davis has been involved in over $2 billion in healthcare deals and nearly $1 billion in royalty financings. He has also led, structured and closed over 40 additional intellectual property licenses, as well as growth equity, and debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm's royalty investments as a member of the royalty management committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Prior to beginning his principal investment career in 2001, Mr. Davis held various sales and product management roles at Abbott Laboratories and worked in business development, operations and licensing at Elan Pharmaceuticals. Mr. Davis holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently serves on the board of Ligand Pharmaceuticals (NASDAQ: LGND).
Michael Christopher has more than 17 years of private equity and investment banking experience. Prior to joining ARM Energy (formerly Asset Risk Management) in 2015 in the role of chief investment officer and chief financial officer, he spent nearly 13 years at ArcLight Capital Partners where he originated and numerous structured private equity transactions. Mr. Christopher began his career in Citigroup’s Investment Banking Group, where he provided M&A and capital markets advice to public and private companies. He earned a B.S. in commerce from The University of Virginia.